Universal Biosensors Inc (ASX:UBI)
Universal Biosensors Inc (ASX:UBI) specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), food and drink and agriculture.
UBI began its journey focusing on the research, development and manufacture of devices for the diagnostic POC market using UBIs core technology of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system that rapidly and accurately measures different biomarkers in blood.
This led UBI to develop a blood glucose monitoring product for LifeScan, Inc. (a Johnson & Johnson company) which was launched in 2010 under the global brand of OneTouch Verio. This was soon followed by the development of a Prothrombin Time (PT/INR) blood coagulation analyser and test strip for Siemens Healthcare which was launched in 2014 under the global brand of Xprecia Stride, to help patients taking the anticoagulant drug Warfarin manage their medication.
UBIs innovative electrochemical sensor platform is being applied to a range of other medical diagnostic applications.
Building upon the success of these globally launched products, UBI continues to focus on the diagnostic POC market and is now exploring the opportunities this technology offers of speed, ease of use, reliability, accuracy at a low cost in alternative industries.